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the elevation of serum Lp(a) levels in patients with moderateLipoprotein(a) and apolipoprotein(a) isoforms and proteinuria
impairment of renal function. The elevation of Lp(a) levelsin patients with moderate renal failure.
occurs independently of the level of proteinuria and may con-Background. Atherosclerotic diseases are a major cause of
tribute to the risk for atherosclerotic disease in these patients.death in patients with renal failure. Increased serum concentra-
tions of lipoprotein(a) [Lp(a)] have been established as a genet-
ically controlled risk factor for these diseases and have been
demonstrated in patients with moderate renal failure, sug-
Cardiovascular events are a major cause of death ingesting that this lipoprotein contributes to the increased cardio-
patients with end-stage renal failure [1]. The propensityvascular risk seen in these patients. Variable alleles at the
apolipoprotein(a) [apo(a)] gene locus are the main determi- of renal failure patients to develop cardiovascular dis-
nants of the serum Lp(a) level in the general population. The ease is influenced by many risk factors, such as age,
purpose of this study was to investigate apo(a) isoforms in hypertension, lipoprotein abnormalities, diabetes, andpatients with moderate renal failure and mild proteinuria (less
increased circulating levels of homocysteine and fibrin-than 1.0 g/day).
Methods. In 250 consecutive subjects recruited at a hyper- ogen [1–5]. Among these risk factors, lipoproteins are
tension clinic, we assessed the renal function by 24-hour creati- fundamental to the atherosclerotic process and greatly
nine clearance, proteinuria, and microalbuminuria, as well as affect the impact of renal failure on cardiovascular mor-
the prevalence of atherosclerotic disease, and we also measured
bidity and mortality. Lipoprotein(a) [Lp(a)] is a hetero-apo(a) isoforms, serum albumin, and Lp(a) concentrations.
geneous lipoprotein [6] that incorporates a low-densityResults. Moderate impairment of renal function (creatinine
clearance, 30 to 89 ml/min per 1.73 m2 of body surface area) lipoprotein (LDL) particle and the highly polymorphic
was found in 97 patients. Lp(a) levels were significantly greater apolipoprotein(a) [apo(a)], which is covalently bound to
in patients with moderate renal failure (21.7 6 23.9 mg/dl) as the apolipoprotein B moiety of LDL by a disulfide bridgecompared with patients with normal renal function (15.6 6
[7–9]. Serum Lp(a) concentrations vary over a broad16.4 mg/dl, P , 0.001), and an inverse correlation was observed
range (from , 0.1 to . 100 mg/dl) in Caucasian (white)between log Lp(a) and creatinine clearance (r 5 20.181, P ,
0.01). However, no difference was found in the frequency of populations, with a distribution that is skewed at low
low molecular weight apo(a) isoforms between patients with levels [10]. The apo(a) gene is located on chromosome
normal (25.5%) and impaired (27.8%) renal function. Only
6 (6q2.6-2.7) and is the major gene controlling serumpatients with the smallest size apo(a) isoforms exhibited sig-
Lp(a) concentrations [11, 12]. The alleles expressed atnificantly elevated levels of Lp(a), whereas the large-size iso-
forms had similar concentrations in patients with normal and this highly polymorphic locus determine a size polymor-
impaired renal function. No significant relationship was found phism of apo(a) that results from differences in the num-
between serum Lp(a) and proteinuria. Clinical and laboratory ber of kringle-IV repeats [10–12]. An inverse relation-evidence of one or more events attributed to atherosclerosis
ship has been demonstrated between plasma Lp(a)was found in 9.8% of patients with normal renal function and
concentrations and the size of apo(a) [10].25.8% of patients with moderate renal failure (P , 0.001).
Conclusions. These results indicate that renal failure per se Prospective and retrospective epidemiological studies
or other genes beside the apo(a) gene locus are responsible for have shown that elevated serum Lp(a) concentrations are
an independent risk factor for cardiovascular disease in
the general population [reviewed in 13, 14], although thisKey words: lipids, cardiovascular disease, proteinuria, atherosclerotic
disease, hypertension. association was not confirmed in two studies [15, 16]. The
mechanisms for the pathogenicity of Lp(a) are unknown,
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trations have been consistently reported in patients with 1999 by the International Society of Nephrology
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nephrotic syndrome [18], end-stage renal failure treated mm Hg, taken during a period of four weeks. The body
mass index (weight/height squared) was used as a mea-by dialysis [18], and moderate renal failure treated con-
servatively [19–23]. This observation led us to hypothe- sure of overall obesity. All patients had measurements
of 24-hour creatinine clearance and urinary protein ex-size a contribution of Lp(a) to the increased frequency
of cardiovascular events in renal failure patients. cretion [29]. Impairment of renal function was consid-
ered to be present when the 24-hour creatinine clearanceThe evaluation of apo(a) phenotypes in dialysis pa-
tients demonstrates that the elevation of serum Lp(a) is was less than 90 ml/min/1.73 m2 of body surface area.
The cause of renal failure was established by history,associated with a frequency distribution of apo(a) iso-
forms that is comparable to normal, suggesting that non- urinalysis, and review of medical records.
The cardiovascular status was assessed in all patientsgenetic factors related to renal insufficiency or genes
different from the apo(a) gene are involved in Lp(a) by a complete history, physical examination, and electro-
cardiogram. Additional laboratory tests, including echo-elevation [24]. However, dialysis patients have several
well-characterized abnormalities of lipoprotein metabo- cardiography, treadmill exercise stress testing, myocar-
dial perfusion scan, coronary arteriography, ultrasoundlism [25, 26] that are affected by the type of dialysis
treatment [26]. Therefore, the relationships between examination of abdominal aorta, carotid, iliac, and femo-
ral arteries, and cerebral single photon emission com-Lp(a), apo(a) isoforms and renal function should be bet-
ter evaluated in renal failure patients in a preuremic puted tomography, were performed when appropriate
[30]. The retrospective diagnosis of myocardial infarctionstage. In this study, we have evaluated apo(a) isoforms
and the relationships between Lp(a) and proteinuria in was confirmed by documented history, electrocardio-
graphic changes, and a greater than twofold elevationa large group of patients with moderate renal failure.
of the serum creatine kinase with positive MB fraction.
The neurologic diagnosis of transient ischemic attack,
METHODS
prolonged reversible ischemic neurologic deficits, and
Patients and study design atherothrombotic stroke was confirmed by documented
history, clinical signs, and computerized cerebral axialTwo hundred and fifty white patients (aged 53 6 12
years; 122 males and 118 females) who were referred tomography. The assessment of the cardiovascular status
was done without prior knowledge of patients’ creatinineconsecutively to the hypertension clinic of our depart-
ment from January 1993 to December 1995 were in- clearance and serum lipoproteins levels.
The hypertensive patients taking antihypertensivecluded in a cross-sectional study. The patients seen at
the clinic include (a) patients with established diagnosis drugs were withdrawn from treatment one week before
measurement of blood parameters and renal function.of arterial hypertension; (b) patients referred for evalua-
tion of blood pressure-related problems (family history None of the patients were taking lipid-lowering drugs at
the time of the study. At the time of the study, patientsof hypertension and other cardiovascular diseases, occa-
sional finding of high or low blood pressure, and ambula- were allowed to maintain their usual unrestricted diet.
Venous blood samples were obtained from all patientstory blood pressure monitoring); and (c) normotensive
subjects who wish to have their blood pressure measured after fasting for 12 to 14 hours for analysis of serum
triglycerides, total and high-density lipoprotein (HDL)and receive counseling. Exclusion criteria were a body
mass index of greater than 30 kg/m2, pregnancy, diabetes cholesterol, Lp(a), and apo(a) isoforms.
mellitus or other endocrine diseases, severe hypertension
Laboratory measurementsdefined as diastolic blood pressure of 115 mm Hg or
higher, renal failure with creatinine clearance of less than Total cholesterol and triglycerides were assayed en-
zymatically by an automated method (International30 ml/min/1.73 m2 of body surface area, urinary protein
excretion of greater than 1.0 g/day; the presence of other Laboratory, Milan, Italy). HDL cholesterol was assayed
enzymatically after magnesium chloride-dextran sulfatediseases or treatments that might interfere with serum
lipids. Because Lp(a) is an acute phase reactant, we also precipitation of apoB-containing lipoproteins. The con-
centration of LDL cholesterol was calculated with theexcluded all the patients with acute illness and recent
(within six months) myocardial infarction, unstable an- formula of Friedewald, Levy, and Friedrickson [31]. Se-
rum levels of apoA-I and B were measured by an immu-gina, or stroke. Blood pressure was measured by mercury
sphygmomanometry (Korotkoff phase V) [27] after each noturbidimetric method (Eiken, Tokyo, Japan) [32].
Lp(a) was measured on samples that had been frozenpatient had been supine for 15 minutes. The average of
three readings obtained in five minutes was recorded. at 2708C. All samples were less than four weeks old and
had been stored for an average time of three weeks.Arterial hypertension was diagnosed according to the
World Health Organization/International Society of Hy- The Lp(a) concentration was determined with a double-
antibody enzyme-linked immunosorbent assay (Strate-pertension Guidelines [28] after at least three separate
measurements of diastolic blood pressure higher than 90 gic Diagnostic, Newark, NJ, USA) employing a mouse
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monoclonal anti-Lp(a) antibody for coating and a horse- Serum Lp(a) concentrations were significantly greater
radish peroxidase (HRP)-conjugated polyclonal goat anti- in the patients with creatinine clearance of less than 90
Lp(a) antibody for detection [30]. All measurements ml/min/1.73 m2 than in those with a creatinine clearance
were done in duplicate. The interassay and intra-assay of 90 ml/min/1.73 m2 or more (Table 2). These increased
variability for Lp(a) measurements was 8.6 and 6.3%, levels of Lp(a) were also demonstrated by the frequency
respectively. Apo(a) phenotyping was performed by so- distribution graph in Figure 1. Stratified analysis of serum
dium dodecyl sulfate-agarose gel electrophoresis under Lp(a) levels in patients with different degree of renal
reducing conditions, followed by immunoblotting with function impairment indicated that higher serum concen-
the monoclonal antibody 1A2 for the detection of apo(a) tration of this lipoprotein was associated not only with
phenotypes [30, 33]. the presence of renal failure but also with its severity
(Fig. 2). The log serum Lp(a) concentration was inversely
Statistical analysis correlated (r 5 20.181, P , 0.01) with creatinine clear-
All values are expressed as means 6 sd. Because the ance and directly correlated with apoB levels (r 5 0.201,
distribution of Lp(a) values was significantly skewed, P , 0.01). Lp(a) concentrations were comparable in
logarithmic transformation was performed to obtain nor- renal failure patients with (21.9 6 19.3 mg/dl) and with-
mal distribution. The Student’s t-test for unpaired data out (21.7 6 22.2 mg/dl) persistent microhematuria and
and the Mann–Whitney test were used for comparisons were not correlated with serum albumin levels and uri-
between two groups; two-way analysis of variance and nary protein excretion.
the Kruskal–Wallis test were used for comparisons To investigate whether elevated Lp(a) levels in pa-
among more than two groups. The Pearson’s chi-square tients with moderate impairment of renal function have
test was used to compare frequency distributions. The a genetic background, we analyzed apo(a) phenotypes.
relationships between variables were examined by linear The frequency distribution of the different apo(a) iso-
regression analysis, and the correlation was expressed forms did not differ significantly between patients with
by the correlation coefficient. normal or decreased creatinine clearance (Table 2).
Because of the high number of detectable apo(a) iso- When patients with normal and impaired renal function
forms, many phenotypes were represented in low num- were subdivided into two subgroups with at least one
bers. To obtain sufficient sample sizes, we combined a LMW isoform and only with HMW isoforms, no differ-
priori the apo(a) phenotypes in five subgroups, according ence was observed (Table 2 and Fig. 2). These observa-
to the molecular weight of the smallest apo(a) isoforms tions suggest that the Lp(a) elevation in patients with
(11 to 19, 20 to 22, 23 to 25, 26 to 29, and more than 29 early impairment of renal function has no genetic back-
kringle-IV repeats) [30, 33]. Furthermore, we divided ground. Table 3 shows the average serum Lp(a) levels
the apo(a) phenotypes according to the molecular weight for each of the five apo(a) phenotype subgroups and
of the smallest apo(a) isoforms, as performed in earlier demonstrates the presence of a significant inverse rela-
studies [30, 34–36]. The low molecular weight group tionship between isoform protein size and serum Lp(a)
(LMW) included all the patients with at least one apo(a) levels in patients with both normal and moderately im-
isoform with 11 to 22 kringle-IV repeats; the high molec- paired renal function. When patients with normal and
ular weight group (HMW) included all of the patients decreased creatinine clearance were compared, the aver-
who had only isoforms with more than 22 kringle-IV
age Lp(a) levels were significantly different in only the
repeats. P values below 0.05 were considered to indicate
apo(a) subgroup with the lowest molecular weight. Uri-
statistical significance.
nary protein excretion and creatinine clearance values
were comparable throughout the apo(a) subgroups in
RESULTS patients with both normal and impaired renal function.
Clinical and instrumental evidence of one or moreClinical, lipid, and renal function parameters are sum-
events attributed to atherosclerosis was found in 9.8%marized in Table 1. Creatinine clearance of less than 90
of patients with normal renal function and 25.8% ofml/min/1.73 m2 was found in 97 of 250 patients. Renal
patients with moderate renal failure (Table 4). The prev-failure was caused by arteriolar nephrosclerosis in 94
alence of coronary artery, cerebrovascular, and periph-patients and by chronic glomerulonephritis in 3. Persis-
eral vascular disease was significantly higher in patientstent microhematuria suggestive of proliferative renal dis-
with decreased creatinine clearance than in patients withease was present in 14 of 97 (15%) patients with renal
normal creatinine clearance. The frequency of LMWfailure. Age, systolic blood pressure, and prevalence of
apo(a) isoforms was significantly greater in patients witharterial hypertension were significantly greater in the
evidence of atherosclerotic disease (42.5%) as comparedpatients with creatinine clearance of less than 90 ml/min/
with patients with no evidence of atherosclerotic disease1.73 m2 than in those with a creatinine clearance of 90
ml/min/1.73 m2 or more. (23.3%, P , 0.02).
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Table 1. Clinical, lipid, and renal function parameters in the study patients
Creatinine clearance
$90 ml/min/1.73 m2 30–89 ml/min/1.73 m2
(N 5 153) (N 5 97)
Age years 50.4611.3 59.0612.2a
Systolic blood pressure mm Hg 164623 174624a
Diastolic blood pressure mm Hg 100613 102613
Prevalence of hypertension % 68.6 85.6b
Body mass index kg/m2 27.463.7 26.863.7
Total cholesterol mmol/liter 5.4961.09 5.5961.19
LDL cholesterol mmol/liter 3.5861.09 3.5860.98
HDL cholesterol mmol/liter 1.2760.39 1.3260.36
Triglycerides mmol/liter 1.3760.80 1.4961.00
Apo A-1 mg/dl 154630 151626
Apo B mg/dl 126631 123633
Serum albumin lmol/liter 620671 611669
Serum creatinine lmol/liter 83.2614.1 105.3636.3a
Creatinine clearance ml/min/1.73 m2 121622 67618a
Proteinuria g/day 0.160.1 0.460.2c
To convert to conventional units multiply: serum albumin by 0.0069 (g/dl), cholesterol by 38.6 (mg/dl), triglycerides by 88.5 (mg/dl), and creatinine by 0.0113 (mg/
dl). Data are means 6 sd.
a P , 0.001 by Student’s t-test
b P , 0.01 by the Pearson chi-square test
c P , 0.001 by the Mann-Whitney test
Table 2. Plasma lipoprotein(a) concentrations and frequency of apolipoprotein(a) phenotypes in the study patients
Creatinine clearance
$90 ml /min/1.73 m2 30–89 ml /min/1.73 m2
(N 5 153) (N 5 97)
Lipoprotein(a) mg/dl 15.6616.4 (8.64) 21.7623.9 (13.6)a
Log lipoprotein(a) 0.9160.56 1.03 60.63b
11–19 Kringle-IV repeats 13 [8.5] 8 [8.2]
20–22 Kringle-IV repeats 26 [17.0] 19 [19.6]
23–25 Kringle-IV repeats 20 [13.1] 18 [18.6]
26–29 Kringle-IV repeats 52 [34.0] 34 [35.0]
.29 Kringle-IV repeats 42 [27.4] 18 [18.6]
Low molecular weight 39 [25.5] 27 [27.8]
High molecular weight 114 [74.5] 70 [72.2]
Data are means 6 sd. Data in parentheses indicate median values for variables with skewed distribution. Data in brackets indicate percentages. Apolipoprotein(a)
phenotypes were combined in 5 subgroups, according to the molecular weight of the smallest apolipoprotein(a) isoforms. Furthermore, apolipoprotein(a) phenotypes
were divided according to the molecular weight of the smallest apolipoprotein(a) isoforms (Low molecular weight, subjects with at least one isoform with 11 to 22
kringle-IV repeats; High molecular weight, subjects who had only isoforms with more than 22 kringle-IV repeats).
a P , 0.001 by the Mann-Whitney test
b P , 0.001 by the Student’s t-test
DISCUSSION vated Lp(a) levels are not related to the size polymor-
phism of apo(a) [24, 34], indicating that nongeneticThe results of this study demonstrate that elevated
factors related to renal insufficiency or other genes be-serum Lp(a) concentrations are not related to the size
side the apo(a) gene are involved in Lp(a) elevation.polymorphism of apo(a) in patients with early impair-
However, the relationship between Lp(a) and renal func-ment of renal function and therefore indicate that Lp(a)
tion is difficult to establish in dialysis patients in whom
elevation cannot be explained by variations at the struc- many abnormalities of lipid metabolism have been de-
tural apo(a) gene locus. Elevated Lp(a) levels and mod- scribed [25, 26]. Although many studies have consistently
erate renal failure are associated with an increased preva- reported elevated serum Lp(a) levels in patients with
lence of cardiovascular disease, suggesting a contribution early renal insufficiency treated conservatively [19–23],
of this lipoprotein to the risk for atherosclerotic compli- limited data are available on apo(a) isoforms in these
cations in these patients. patients. This study is the first to show that the frequency
The few studies that have evaluated apo(a) pheno- distribution of apo(a) isoforms in moderate renal failure
is comparable to patients with normal renal function.types in dialysis patients have demonstrated that ele-
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Fig. 1. Distribution of serum lipoprotein(a) con-
centrations in patients with moderate renal failure
(N 5 97) and patients with normal renal function
(N 5 153). Symbols are: (j) creatinine clearance
$90 ml/min/1.73 m2; ( ) creatinine clearance
,90 ml/min/1.73 m2.
nicity. However, if elevated Lp(a) levels are a primary
cause of renal disease, one would expect a different fre-
quency distribution of apo(a) isoforms that was not ob-
served in this study. This finding strongly suggests that
renal failure is the cause of Lp(a) elevation and not the
other way around, adding moderate renal failure to the
nongenetic causes for elevated Lp(a) levels. This possi-
bility is further supported by the recent observation that
urinary apo(a) excretion is decreased in patients with
impaired renal function [38]. Longitudinal studies in pa-
tients with elevated serum Lp(a) concentrations and nor-
mal renal function and patients with progressive renal
failure will help to better discern between these two
possibilities.
Previous studies have demonstrated that in whites,Fig. 2. Frequency of low molecular weight (LMW) apolipoprotein(a)
phenotypes (j) and serum lipoprotein(a) ( ) levels (mean 6 SEM) in 69% of the variance in serum Lp(a) concentrations is
patients with different degrees of renal function impairment and in accounted for by variation in the number of kringle-IVpatients with normal creatinine clearance. The frequency of LMW apoli-
repeats in the apo(a) gene, and an additional 22% ispoprotein(a) isoforms did not differ among the groups. Lipoprotein(a)
levels differed significantly (P , 0.02 by the Kruskal–Wallis test) de- accounted for by the variation of other sequences located
pending on creatinine clearance values. either within or near the apo(a) locus [12]. Accordingly,
studies performed in women twins have shown that se-
rum Lp(a) concentrations are heritable and predomi-
The association between elevated serum Lp(a) con- nantly (. 90%) determined by the apo(a) gene locus
centrations and impaired renal function and the inverse [39], whereas the relative contribution of environmental
correlation between log Lp(a) and creatinine clearance factors to the regulation of serum Lp(a) levels is minimal
might be seen as the result of a primary increase in Lp(a) [6, 17, 40]. In this study, we have observed comparable
promoting renal failure rather than renal failure causing frequency distribution of apo(a) phenotypes in patients
an increase in Lp(a). It has been demonstrated that Lp(a) with normal and decreased creatinine clearance, indicat-
promotes DNA synthesis, cell proliferation, and expres- ing that the elevation of Lp(a) in patients with moderate
sion of protooncogenes in rat mesangial cells (abstract; renal failure has a weak genetic background.
Greiber et al, Nieren und Hochdrukkrankheiten 23:410, The primary site of synthesis of Lp(a) is the liver [41],
1994), and there is evidence showing that Lp(a) inhibits as indicated by the presence of apo(a) messenger RNA
acetylcholine-induced vasodilator response in renal ar- in hepatic tissue obtained from humans and baboons [42,
43]. In vivo turnover studies performed in humans haveteries [37], suggesting possible mechanisms of pathoge-
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Table 3. Serum lipoprotein(a) concentrations of different apolipoprotein(a) phenotypes in the study patients
Creatinine clearance Creatinine clearance
>90 ml/min/1.73 m2 30–89 ml/min/1.73 m2
(N 5 153) (N 5 97)
Lipoprotein(a)a Proteinuria Creatinine clearance Lipoprotein(a)a Proteinuria Creatinine clearance
mg/dl g/day ml/min/1.73 m2 mg/dl g/day ml/min/1.73 m2
11–19 Kringle-IV repeats 27.7615.7 0.2 60.1 116620 46.1615.3b 0.460.1c 60620
20–22 Kringle-IV repeats 24.4621.9 0.1 60.1 119617 36.3636.6 0.560.2c 64621
23–25 Kringle-IV repeats 14.1614.5 0.2 60.1 122620 25.7624.3 0.460.2c 68618
26–29 Kringle-IV repeats 13.8613.0 0.1 60.1 123626 13.7612.5 0.560.3c 69616
.29 Kringle-IV repeats 9.3613.6 0.1 60.1 121622 9.6 66.4 0.460.2c 66619
Data are means 6 sd. Apolipoprotein(a) phenotypes were combined in 5 subgroups, according to the molecular weight of the smallest apolipoprotein(a) isoforms.
a P , 0.001 by Kruskal-Wallis test
b P , 0.05 vs. patients with creatinine clearance > 90 ml/min/1.73 m2
c P , 0.01 vs. patients with creatinine clearance > 90 ml/min/1.73 m2
Table 4. Cardiovascular disease status in the study patients
Patients N (%)
Creatinine clearance Creatinine clearance
>90 ml/min/1.73 m2 30–89 ml/min/1.73 m2
(N 5 153) (N 5 97)
Coronary artery disease 10 (6.5) 15 (15.5)a
Angina pectoris 8 12
Myocardial infarction 2 3
Cerebrovascular disease 3 (2.0) 10 (10.3)b
Atherosclerotic plaquese 2 5
TIA or PRIND 1 1
Atherothrombotic stroke — 4
Peripheral vascular disease 5 (3.3) 12 (12.4)c
Atherosclerotic plaquese 2 6
Symptomatic arterial occlusive disease 3 4
Aortic aneurysm — 2
Total number of events 18 37
Number of subject with events 15 (9.8) 25 (25.8)d
Abbreviations are: TIA, transitory ischemic attack; PRIND, prolonged reversible ischemic neurologic deficit.
a P , 0.05 by Pearson chi-square test
b P , 0.01 by Pearson chi-square test
c P , 0.02 by Pearson chi-square test
d P , 0.001 by Pearson chi-square test
e Carotid arteries, abdominal aorta, and iliac and femoral arteries were evaluated with a B-mode ultrasound system equipped with a 7.5-MHz transducer. Examination
was performed in the supine position and multiple projections were used. Atherosclerotic lesions were defined by the presence of plaques at least 50% greater than
the surrounding wall.
suggested that differences in plasma Lp(a) concentra- sibility of a nonspecific receptor pathway [50], whereas
the scavenger receptor pathway does not appear to betions among individuals are a result of differences in
synthesis rather than differences in catabolism [44, 45]. significantly involved in Lp(a) degradation [51]. Two
possible mechanisms could explain the elevation of Lp(a)The site and mechanism of catabolism of Lp(a), however,
are still subjects of controversy. The LDL receptor does concentrations observed in renal failure. First, the kidney
might have an indirect influence on Lp(a) synthesis innot appear to contribute in a major way, inasmuch as
the absence of functional LDL receptor does not result the liver through some unidentified factor. Alternatively,
the kidney might have a catabolic function on Lp(a),in a delayed catabolism of Lp(a) [46], and hydroxyl-
methyl-glutaryl coenzyme A reductase inhibitors, which as suggested by the demonstration of degraded apo(a)
fragments in urine in an amount that is correlated withincrease LDL receptor activity, have no significant effect
on Lp(a) levels [47]. On the other hand, demonstration the glomerular filtration rate [52]. In support of the latter
hypothesis is also the demonstration of the presence, inof high-affinity binding of Lp(a) to the LDL receptor
[48, 49] and rapid clearance of Lp(a) from the circulation various renal cell types, of the LDL receptor-related
protein [53], a member of the LDL receptor gene family,in mice overexpressing the LDL receptor [48] raise the
possibility of a LDL receptor-mediated pathway in the which might be involved in the catabolism of Lp(a) [54].
Following the observation of increased serum Lp(a)catabolism of Lp(a). Other studies have suggested the pos-
Sechi et al: Apo(a) isoforms in moderate renal failure 1055
concentrations in patients with nephrotic syndrome and In conclusion, this study of a large group of patients
preserved glomerular filtration rate, it has been sug- with moderate renal failure demonstrates that elevated
gested that Lp(a) increases only when serum albumin serum Lp(a) concentrations are probably nongenetic and
decreases. Protein losses, by inducing an increase in he- secondary to renal function impairment. Lp(a) elevation
patic protein synthesis, might play a role in elevation of is not related to the level of proteinuria at this stage of
serum Lp(a) concentrations in renal disease [55]. Al- the renal disease. Although Lp(a) does not seem to be
though an inverse correlation between serum Lp(a) and a primary cause of renal failure, it might contribute to
serum albumin has been demonstrated in some studies the progression of renal disease and to high cardiovascu-
performed in hemodialysis patients [34, 56], none of the lar risk in patients with moderate renal failure, but this
studies conducted in patients with nephrotic syndrome possibility should be investigated further in longitudinal
have confirmed this relationship [57–60]. The patients studies.
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